Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 act mut Dovitinib endometrial cancer sensitive detail...
FGFR2 mutant Infigratinib endometrial cancer sensitive detail...
PIK3CA R88Q PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA R88Q PTEN mut Everolimus endometrial cancer sensitive detail...
PIK3CA R108H PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA R38C PTEN mut Dactolisib endometrial cancer sensitive detail...
PIK3CA E365K PTEN mut Dactolisib endometrial cancer sensitive detail...
PTEN mutant Dactolisib endometrial cancer sensitive detail...
PTEN mutant Everolimus endometrial cancer sensitive detail...
PIK3CA mutant MEN1611 endometrial cancer sensitive detail...
PIK3CA H1047Y MEN1611 endometrial cancer sensitive detail...
PIK3CA R38C PTEN loss MEN1611 endometrial cancer sensitive detail...
FGFR2 C383R FGFR2 N550K PD173074 endometrial cancer resistant detail...
FGFR2 N549K Ponatinib endometrial cancer sensitive detail...
FGFR2 N549K Dovitinib endometrial cancer decreased response detail...
FGFR2 N549K Cediranib endometrial cancer sensitive detail...
FGFR2 N549K Nintedanib endometrial cancer resistant detail...
FGFR2 N549K Brivanib endometrial cancer no benefit detail...
FGFR2 S252W Ponatinib endometrial cancer sensitive detail...
FGFR2 S252W Cediranib endometrial cancer sensitive detail...
FGFR2 S252W Brivanib endometrial cancer sensitive detail...
FGFR2 S252W Nintedanib endometrial cancer sensitive detail...
FGFR2 wild-type Ponatinib endometrial cancer resistant detail...
FGFR2 S252W Dovitinib endometrial cancer decreased response detail...
FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 S252W Debio 1347 endometrial cancer sensitive detail...
PIK3CA mutant Pictilisib endometrial cancer sensitive detail...
PTEN mutant Temsirolimus endometrial cancer no benefit detail...
PTEN mutant GSK2636771 endometrial cancer resistant detail...
PTEN mutant AZD6482 endometrial cancer resistant detail...
PTEN mutant TGX-221 endometrial cancer resistant detail...
PTEN mutant A66 endometrial cancer resistant detail...
PTEN mutant A66 + AZD6482 endometrial cancer sensitive detail...
PTEN mutant A66 + GSK2636771 endometrial cancer sensitive detail...
PIK3CA mutant Apitolisib endometrial cancer sensitive detail...
PTEN mutant Apitolisib endometrial cancer sensitive detail...
ALK wild-type Dalantercept endometrial cancer no benefit detail...
CTNNB1 mutant Temsirolimus endometrial cancer predicted - sensitive detail...
PIK3CA mutant Temsirolimus endometrial cancer no benefit detail...
HRAS mutant Trametinib endometrial cancer sensitive detail...
FGFR2 mutant PRN1371 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K AZD4547 endometrial cancer sensitive detail...
FGFR2 N550K AZD4547 endometrial cancer predicted - sensitive detail...
FGFR2 S252W AZD4547 endometrial cancer decreased response detail...
FGFR2 over exp AZD4547 endometrial cancer resistant detail...
FGFR2 wild-type AZD4547 endometrial cancer resistant detail...
FGFR2 amp AZD4547 endometrial cancer sensitive detail...
FGFR2 S252W E7090 endometrial cancer sensitive detail...
PIK3CA R93W PIK3CA D350G PTEN R130G Miransertib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Infigratinib + Pictilisib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Buparlisib + Infigratinib endometrial cancer sensitive detail...
FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs Alpelisib + Infigratinib endometrial cancer sensitive detail...
FGFR2 S252W Derazantinib endometrial cancer sensitive detail...
FGFR2 N549K Derazantinib endometrial cancer sensitive detail...
PIK3CA mutant Alpelisib endometrial cancer sensitive detail...
CTNNB1 mutant Cabozantinib endometrial cancer predicted - sensitive detail...
PIK3CA mutant MK2206 endometrial cancer no benefit detail...
ARID1A mutant unspecified PD-L1 antibody endometrial cancer predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody endometrial cancer predicted - sensitive detail...
PIK3CA mutant Perifosine endometrial cancer not predictive detail...
FGFR2 K310R FGFR2 N550K Infigratinib + Navitoclax endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K Infigratinib endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K PD173074 endometrial cancer sensitive detail...
FGFR2 C383R AZD4547 endometrial cancer sensitive detail...
FGFR2 C383R Infigratinib endometrial cancer sensitive detail...
FGFR2 C383R PD173074 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 C383R ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + AZD4547 endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + Infigratinib endometrial cancer sensitive detail...
FGFR2 N550K ABT-737 + PD173074 endometrial cancer sensitive detail...
FGFR2 N550K PD173074 endometrial cancer predicted - sensitive detail...
FGFR2 N550K Infigratinib endometrial cancer predicted - sensitive detail...
MLH1 negative Dostarlimab-gxly endometrial cancer sensitive detail...
MSH6 negative Dostarlimab-gxly endometrial cancer sensitive detail...
PTEN inact mut LY3023414 endometrial cancer no benefit detail...
PIK3CA act mut LY3023414 endometrial cancer no benefit detail...
FGFR2 N549K RLY-4008 endometrial cancer predicted - sensitive detail...
FGFR2 K310R FGFR2 N549K Futibatinib endometrial cancer predicted - sensitive detail...
FGFR2 N549K Futibatinib endometrial cancer predicted - sensitive detail...
FGFR2 S252W Futibatinib endometrial cancer predicted - sensitive detail...
MLH1 negative Pembrolizumab endometrial cancer sensitive detail...
MSH6 negative Pembrolizumab endometrial cancer sensitive detail...
MLH1 negative Avelumab endometrial cancer sensitive detail...
MSH6 negative Avelumab endometrial cancer sensitive detail...
MLH1 negative Durvalumab endometrial cancer sensitive detail...
MSH6 negative Durvalumab endometrial cancer predicted - sensitive detail...
FGFR2 N550K TYRA-200 endometrial cancer predicted - sensitive detail...
PIK3CA H1047R Alpelisib endometrial cancer predicted - sensitive detail...
MLH1 negative Carboplatin + Dostarlimab-gxly + Paclitaxel endometrial cancer sensitive detail...
MSH6 negative Carboplatin + Dostarlimab-gxly + Paclitaxel endometrial cancer sensitive detail...
FGFR2 C382R Erdafitinib endometrial cancer predicted - sensitive detail...
FGFR2 Y375C Erdafitinib endometrial cancer predicted - sensitive detail...
PTEN K6fs TAS0612 endometrial cancer sensitive detail...
PTEN L320* TAS0612 endometrial cancer sensitive detail...
MSH6 negative Nivolumab endometrial cancer sensitive detail...
MLH1 negative Nivolumab endometrial cancer sensitive detail...
MLH1 negative Atezolizumab endometrial cancer sensitive detail...
MSH6 negative Atezolizumab endometrial cancer sensitive detail...
FGFR2 amp CPL304110 endometrial cancer sensitive detail...
FGFR2 N549K 3HP-2827 endometrial cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01379534 Phase II Dovitinib A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed USA | NZL | ITA | GBR | ESP 2
NCT01697566 Phase III Metformin An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting USA 0
NCT01797523 Phase II Letrozole Everolimus Metformin RAD/Letrozole/Metformin Active, not recruiting USA 0
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT01935934 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT02035787 Phase I Metformin Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Active, not recruiting USA 0
NCT02042495 Phase II Metformin Endometrial Cancer Biomarker Changes Following Exposure to Metformin Withdrawn CAN 0
NCT02188550 Phase II Everolimus + Letrozole Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status USA 0
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Completed USA 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Terminated USA 1
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | ESP 1
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Active, not recruiting USA | ITA | GBR | ESP 2
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Completed USA | ESP | CAN | BEL 0
NCT02630823 Phase I Carboplatin + Paclitaxel + Pembrolizumab MK-3475 Immunotherapy in Endometrial Carcinoma Completed USA 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Completed USA 0
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT02684227 Phase II Carboplatin + Enzalutamide + Paclitaxel Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer Completed USA 0
NCT02715284 Phase I Dostarlimab-gxly A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting USA | ITA | GBR | FRA | ESP | CAN 7
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Completed USA 0
NCT02728258 Phase II Copanlisib Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed USA 0
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Completed USA 0
NCT02788708 Phase I Lenvatinib + Paclitaxel Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Completed USA 0
NCT02899793 Phase II Pembrolizumab Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Active, not recruiting USA 0
NCT02912572 Phase II Avelumab + Talazoparib Avelumab Avelumab + Axitinib Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Active, not recruiting USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02996825 Phase I Gemcitabine + Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Completed USA 0
NCT03016338 Phase II Niraparib Study of Niraparib in Recurrent Endometrial Cancer Active, not recruiting CAN 0
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting USA 0
NCT03099499 Phase II ONC201 Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer Terminated USA 0
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Completed USA | ESP | BEL | AUS 0
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Active, not recruiting USA 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Recruiting USA | GBR 0
NCT03300557 Phase II Exemestane Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer Active, not recruiting USA 0
NCT03310567 Phase II Epacadostat + Pembrolizumab A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma Withdrawn USA 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA | AUS 0
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Completed FRA | BEL 0
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Completed USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03474640 Phase I Toripalimab-tpzi Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Unknown status USA 0
NCT03485729 Phase II ONC201 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Active, not recruiting USA 0
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Active, not recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03555422 Phase III Selinexor Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) Active, not recruiting USA | ITA | ESP | DEU | CAN | BEL 4
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Terminated USA 0
NCT03617679 Phase I Rucaparib Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03643510 Phase II Abemaciclib + Fulvestrant Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03671811 Phase II Megestrol acetate + Pterostilbene Megestrol acetate Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy Active, not recruiting USA 0
NCT03675893 Phase II Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer Recruiting USA 0
NCT03745950 Phase II Olaparib UTOLA: UTerin OLAparib (UTOLA) Active, not recruiting FRA 0
NCT03748186 Phase I Luveltamab Tazevibulin Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Recruiting USA | ESP 0
NCT03835819 Phase II Mirvetuximab Soravtansine + Pembrolizumab A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Recruiting USA 0
NCT03905148 Phase Ib/II Lifirafenib + PD-0325901 Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Recruiting USA | AUS 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Active, not recruiting USA | FRA | ESP | CAN | BEL | AUS 2
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Recruiting USA 0
NCT03981796 Phase III Carboplatin + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) Active, not recruiting USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL 12
NCT04008797 Phase I Lenvatinib E7386 + Lenvatinib A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor Recruiting USA | FRA 3
NCT04044859 Phase I ADP-A2M4 cells ADP-A2M4 cells + Pembrolizumab ADP-A2M4 cells + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04122625 Phase Ib/II Nivolumab + Xevinapant Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Completed USA | FRA | ESP 0
NCT04145622 Phase Ib/II Ifinatamab deruxtecan Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Active, not recruiting USA | AUS 3
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04188548 Phase I Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) Active, not recruiting USA | FRA | ESP | BEL | AUS 3
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Withdrawn 0
NCT04214067 Phase III Pembrolizumab Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Active, not recruiting USA 1
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA | GBR | FRA | ESP 0
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting USA 1
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Active, not recruiting USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04463771 Phase II Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) Recruiting USA | ITA | FRA | DEU | BEL 3
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Recruiting USA | NLD | ITA | GBR | ESP | CAN | BEL | AUS 9
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04498520 Phase I Abexinostat + Fulvestrant + Palbociclib Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Withdrawn 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Active, not recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | FRA | ESP | CAN 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Active, not recruiting USA 0
NCT04774419 Phase II Dostarlimab-gxly Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery Active, not recruiting USA 0
NCT04781088 Phase II Lenvatinib + Paclitaxel + Pembrolizumab Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Completed ESP 1
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 8
NCT05039801 Phase I Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05041972 Phase II ARX-788 ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) Withdrawn USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05067972 Phase I PF-07260437 A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) Terminated USA 1
NCT05082025 Phase II Copanlisib + Fulvestrant Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Active, not recruiting USA 0
NCT05092373 Phase I Cabozantinib Atezolizumab + Nab-paclitaxel Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05112601 Phase II Ipilimumab + Nivolumab Nivolumab Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Recruiting USA 0
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | NLD | GBR | ESP | CAN | BEL | AUS 7
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05229900 Phase I SGN-ALPV A Study of SGN-ALPV in Advanced Solid Tumors Terminated USA | GBR | ESP | CAN 1
NCT05252416 Phase Ib/II BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant (VELA) Study of BLU-222 in Advanced Solid Tumors Recruiting USA | ITA | GBR 0
NCT05262530 Phase Ib/II BNT142 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors Recruiting USA | GBR | ESP 1
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05263492 Phase II Lenvatinib + Pembrolizumab Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer Recruiting USA 0
NCT05277051 Phase I GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN | AUS 3
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05317078 Phase I AMG 794 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Active, not recruiting USA | AUS 1
NCT05394103 Phase Ib/II Q901 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Recruiting USA 1
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05419817 Phase II Pembrolizumab + Sitravatinib Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Withdrawn 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Recruiting USA | AUS 0
NCT05523440 Phase II Bevacizumab + Niraparib Niraparib Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Recruiting USA 0
NCT05527184 Phase I IMGN151 First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Recruiting USA 0
NCT05554328 Phase II Selumetinib Olaparib + Selumetinib Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Recruiting USA 1
NCT05572684 Phase Ib/II NC410 + Pembrolizumab A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Recruiting USA 0
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05634499 Phase II Giredestrant A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA) Recruiting USA | ITA | CAN 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05650203 Phase I JS006 + JS009 + Toripalimab-tpzi JS009 A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Withdrawn 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05655598 Phase I Palbociclib + Pimitespib TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Recruiting USA 0
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05691504 Phase I APG-1252 + Cobimetinib Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Recruiting USA 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05731271 Phase Ib/II TST003 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Recruiting USA 0
NCT05761951 Phase II DKN-01 + Pembrolizumab Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer Recruiting USA 0
NCT05797831 Phase II KRT-232 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Recruiting USA | ITA | ESP | CAN | AUT 12
NCT05798611 Phase II ART0380 Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Recruiting USA | FRA 0
NCT05819892 Phase I Cisplatin + Dostarlimab-gxly + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer Recruiting USA 0
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT06036836 Phase II Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Recruiting USA | NLD | FRA | CAN | AUS 3
NCT06040970 Phase Ib/II Cisplatin + Sacituzumab govitecan-hziy Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Not yet recruiting USA 0
NCT06129604 Phase II TPST-1495 Pilot Window of Opportunity Trial (POET) Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06180733 Phase II Pembrolizumab Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) Recruiting NLD 0
NCT06218914 Phase I NT-112 A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06253494 Phase Ib/II HER2 Vaccine + Lenvatinib + Nogapendekin alfa inbakicept + Pembrolizumab HER2 Vaccine + Lenvatinib + Pembrolizumab Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer Suspended USA 0
NCT06264921 Phase I NKT3447 A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06276491 Phase I XmAb541 Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors Recruiting USA 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06293898 Phase I BL-M07D1 Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors Recruiting USA 0
NCT06330064 Phase II Ifinatamab deruxtecan A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors Recruiting USA 0
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0
NCT06400472 Phase I LY4170156 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Recruiting USA 0